Idiopathic short stature (ISS) refers to children with shorten growth of body where the reason behind the physical condition is unknown. The children with height less than 2 standard deviations (SDs) are categorized in this clinical condition. The group of idiopathic short children includes children with delay of growth and puberty, hereditary short stature, children with subtle cartilage and bone dysplasias. There is no precise medical cause for ISS, whereas some reasons include genetic structure and other orthopedic related complications.
View Report –
The disease often diagnosed by X-rays of the left wrist or hand along with complete blood count, growth hormone stimulation test, insulin growth factor-1 test and other blood related tests. Though there is ongoing debate about treatment of ISS based on growth hormones but based on the physical and blood test, generally hormonal therapy is recommended by health care professionals In 2003, United States Food and Drug Administration (FDA) approved human growth hormone treatment for children with idiopathic short stature (height below 2.25 SD). According to survey conducted by European Society of Endocrinologist, 94% physicians prefer growth hormone treatment for ISS.
Children with idiopathic short stature can be found in all parts of the world. According to The Endocrine Society based in United States, It is estimated that approximately 60 – 80% of all children across the globe with short stature fit in the category of ISS and therefore total number of people living with ISS will increase accordingly. The above fact stands for demand of various treatment options for ISS globally. The heavy investment in research and development, suitable reimbursement conditions and growing number of patients living with ISS may drive the growth of the market. On the other hand limited awareness and lack of specific treatment may hinder the growth of the overall market.
Request to View Brochure of Report –
Currently there are many clinical research projects under study that are focused on developing specific treatment for idiopathic short stature. Merck KGaA has “Saizen” in pipeline for treatment of affected children, Pfizer in collaboration with prestigious Rabin Medical Center exploring the use of biochemical markers of growth with growth hormone treatment, Eli Lilly and Company trying to develop monotherapy of somatropin in pubertal children with ISS, Dong-A Pharmaceutical Co., Ltd. is studying the improvement of height of children by growth hormone therapy.
Idiopathic short stature market can be segmented according to different categories such as regional geography, classification of ISS and categories of drugs available for the treatment. Geographically, this market can be segmented in four regions namely North American, Europe, Asia-Pacific and Rest of the World, out of all these segments North America region have highest contribution in terms of value because of high awareness, higher percentage of total income spent on healthcare compared to other economies and appropriate reimbursement circumstances. Followed by this, Europe, Asia-Pacific and Rest of the World respectively could be major segments of the market. The treatment market can also be segmented according to categories such as familial ISS and non-familial ISS. According to treatment options available, the market for ISS can be segmented in Growth hormones, genetic therapy and others.
Request to View ToC of the report –
Currently many established players in pharmaceuticals market which are either catering or on the way to develop drugs for idiopathic short stature. Out of these companies, JCR Pharmaceuticals Co., Braasch Biotech LLC, Bolder Biotechnology, Inc., Myungmoon pharmaceutical Co. Ltd, Eli Lilly, Pfizer are leading contributors.